Kura Oncology, Inc.
(NASDAQ : KURA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.90%194.181.2%$592.16m
GILDGilead Sciences, Inc.
-0.83%69.200.9%$496.51m
BIIBBiogen Inc.
0.72%324.051.3%$476.94m
CELGCelgene Corporation
-0.47%69.651.2%$474.00m
ILMNIllumina, Inc.
0.13%319.933.5%$402.89m
REGNRegeneron Pharmaceuticals, Inc.
1.08%345.332.6%$297.08m
VRTXVertex Pharmaceuticals Incorporated
-0.94%165.111.9%$277.86m
ALXNAlexion Pharmaceuticals, Inc.
-0.89%118.622.0%$201.35m
AAgilent Technologies, Inc.
0.42%64.991.5%$188.27m
EXASExact Sciences Corporation
3.65%71.3825.3%$147.45m
SRPTSarepta Therapeutics, Inc.
0.07%119.0415.4%$145.09m
LGNDLigand Pharmaceuticals Incorporated
1.68%154.4623.3%$145.09m
ECYTEndocyte, Inc.
0.25%23.672.0%$124.13m
INCYIncyte Corporation
2.28%66.512.5%$117.76m
NKTRNektar Therapeutics
0.11%38.235.6%$117.70m

Company Profile

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.